| Similar Articles |
|---|
 |
The Motley Fool
July 22, 2005
Karl Thiel |
Cancer Drug: A Shot at Success Cancer vaccine pioneer Dendreon delivered news yesterday that its investors have been anxiously awaiting: final three-year survival data from a phase 3 study of Provenge, the company's flagship prostate cancer vaccine.   |
BusinessWeek
April 30, 2007
Catherine Arnst |
Teaching The Body To Fix Itself Cancer vaccines still in trial stages may be able to prolong life with few side effects, but the FDA has yet to be convinced. |
The Motley Fool
June 29, 2011
Brian Orelli |
4 Immunotherapies to Watch Just don't go all-in. |
The Motley Fool
May 10, 2005
Charly Travers |
Dendreon in the Spotlight The small biotech's prostate cancer drug is in phase 3 development. Is this company worth investing in? |
Scientific American
November 2008
Jessica Wapner |
Cancer Vaccine: Looking Beyond Tumor Size Proponents see hope in changing cancer vaccines' bad reputation |
The Motley Fool
May 4, 2009
Robert Steyer |
Beyond Provenge -- The Next Hot Cancer Drug? The search for prostate cancer treatments is filled with prospects and littered with failures. Which companies have the best chance of success? |
The Motley Fool
April 3, 2007
Brian Lawler |
Dendreon's Positive Panel Surprise Shares of the drugmaker jump after a FDA advisory panel finds in favor of its lead cancer compound. |
The Motley Fool
January 11, 2005
Charly Travers |
The Future of Cancer Vaccines Biotech companies developing cancer vaccines have been in investors' doghouses for a long time. Can a vaccine help stave off forms of the disease? |
Chemistry World
April 17, 2008
Nuala Mora |
World's first therapeutic cancer vaccine approved In move that will be a fillip to cancer vaccine developers, US biotech Antigenics has won Russian approval to market Oncophage to treat kidney cancer. |
The Motley Fool
August 9, 2010
Luke Timmerman |
Kaleetan Seeks to Stand on Dendreon's Shoulders Kaleetan Pharmaceuticals tries to improve upon Dendreon's breakthrough cancer drug. |
HHMI Bulletin
Nov 2010
Amy Maxmen |
Driving the Immune System to Attack Cancer A researcher's longtime efforts to drive T cells to attack tumors hits pay dirt. |
Pharmaceutical Executive
July 1, 2011
Dickmeyer & Rosenbeck |
From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition? |
Chemistry World
March 4, 2011
Elinor Richards |
Laser treatment for late-stage cancer Scientists from China, the US and Peru claim to have successfully treated late-stage breast cancer patients using laser immunotherapy to stimulate patients' own immune systems to fight the cancer. |
The Motley Fool
December 31, 2010
Brian Orelli |
CEL-SCI Investors Cheer a Bit Too Loudly Finally, a phase 3 trial for cancer therapy Multikine. |
AskMen.com
Jacob Franek |
New Cancer Therapies As cancer research explodes, the availability of new and innovative interventions is expanding almost daily. |
The Motley Fool
August 18, 2010
Travers & Greer |
Dendreon's Big Pharma Future Dendreon has had success with its prostate cancer treatment Provenge. What does Provenge's success mean for the future of Dendreon? |
The Motley Fool
June 23, 2009
Brian Orelli |
Wonder Drug! Maybe? Get the facts before jumping on this one. |
The Motley Fool
April 5, 2010
Brian Orelli |
1 Month to Go! Is Dendreon a Buy? Only if you understand the risks. |
The Motley Fool
June 17, 2010
Luke Timmerman |
Oncothyreon's Cancer Vaccine Back in the Saddle as Merck KGaA Re-Starts Clinical Trials The German-based Merck got clearance from the FDA and local ethics review boards to resume two of three large pivotal trials. |
The Motley Fool
May 10, 2006
Brian Lawler |
Dendreon Drives On Will the FDA say yes to a new cancer drug? Investors, take note. |
Scientific American
March 2009
Elaine Schattner |
A Chip against Cancer: Microfluidics Scrutinizes T Cells With just a blood sample, a device could determine whether cancer is about to spread or monitor the progress of treatment |
The Motley Fool
September 22, 2010
Brian Orelli |
A Dendreon Deal: It's Not What You Think Dendreon gets help manufacturing Provenge, but there's still work ahead. |
The Motley Fool
November 10, 2006
Brian Lawler |
Dendreon Pending Approval A lot is riding on what the FDA will say about the small pharma's drug for prostate cancer. Investors, take note. |
The Motley Fool
May 3, 2005
Karl Thiel |
Is Dendreon a Rule Breaker? In working to bring the first therapeutic cancer vaccine to market, the company has faced numerous unknowns and challenges. At this stage, it has produced a fair bit of data that investors can use to size up the firm's prospects, but ultimately, you're either a believer or you're not. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
Chemistry World
June 12, 2012
Nina Notman |
Three pronged approach puts brakes on US breast cancer The US Food and Drug Administration (FDA) has approved the use of anti-HER2 therapy Perjeta (pertuzumab) to treat patients with previously untreated HER2-positive metastatic breast cancer. |
BusinessWeek
May 27, 2010
Pettypiece & Gibson |
Training the Immune System to Fight Cancer Bristol-Myers' new melanoma drug may be a "game changer." |
The Motley Fool
February 24, 2004
David Nierengarten |
Cell Genesys Boosted Cell Genesys's shares jump a day late and a dollar higher. |
The Motley Fool
November 16, 2010
Luke Timmerman |
Dendreon Prepares to Take Some Heat Over Cancer Drug Prices Dendreon looking for off-label uses for its prostate cancer drug. |
Managed Care
March 2007
Martin Sipkoff |
Managing Cancer Treatment Begins Before Diagnosis Health plans are increasingly involved in promoting the lifestyle changes that help their members avoid cancer, and are increasingly involved in clinical trials if prevention fails. |
The Motley Fool
August 10, 2011
Jim Mueller |
Rising Star Buy: Digging Dendreon After getting hammered, there's an opportunity here. |
AskMen.com
Jacob Franek |
Prostate Cancer Overview Everything you wanted to know and more about prostate cancer in this three-part prostate cancer guide. |
The Motley Fool
May 16, 2007
Brian Lawler |
GPC's Next Cancer Drug? GPC Biotech prepares for its future as it awaits an FDA decision on its lead drug. Investors, take note. |
The Motley Fool
May 9, 2007
Brian Lawler |
Diagnosing Dendreon Postmortem The FDA issues an approvable letter for Dendreon's top compound. Investors, take note. |
The Motley Fool
February 7, 2011
Brian Orelli |
Zibotentan Stopped, Long Live Provenge (for Now) Dendreon is looking good although it's not out of the woods yet. |
The Motley Fool
May 21, 2007
Mike Havrilla |
Allos Aligned for Success With two drugs that both sport reasonable chances of positive clinical data and FDA approval, biotech investors should take a look at Allos -- before any potential good news rolls in. |
Nurse Practitioner
October 2009
Wallace et al. |
Shedding light on prostate cancer This article will discuss the risk factors, signs and symptoms, diagnosis of prostate cancer, and disease staging and grading, as well as necessary lab and diagnostic tests, treatment options and patient education. |
HHMI Bulletin
Aug 2011
Richard Saltus |
T-Cell Booster Kits A bioengineer remodels cell surfaces to prod the immune system. |
The Motley Fool
June 1, 2010
Brian Orelli |
Save Your Money, Dendreon As much as doctors would like to prescribe Dendreon's Provenge for their patients, manufacturing limitations will keep demand outpacing supply for awhile. |
The Motley Fool
March 13, 2008
Brian Lawler |
Dendreon Rolls the Dice The pharmaceutical amends a phase 3 study on its lead prostate cancer drug. |
The Motley Fool
November 3, 2011
David Williamson |
Medivation Investors: Why Your Stock Just Jumped 140% Medivation shares pop on trial success for prostate cancer treatment MDV3100. |
American Family Physician
May 15, 2005 |
Early Prostate Cancer: What You Should Know A patient hand-out on the disease, who is at risk, diagnosis and treatment options. |
AskMen.com
Jen Woodward |
Prostate Cancer 101 Here are some of the basic facts about prostate cancer, along with what you can do to keep the C-word from gracing your medical chart. |
Chemistry World
June 11, 2015
Sarah Houlton |
Companies clamour for CAR-T The biopharmaceutical industry is getting excited about chimeric antigen receptor T-cells, or CAR-T cells, designed to harness the cell-killing power of the immune system. |
HHMI Bulletin
Nov 2010 |
Fusion genes that drive solid tumors are a new target for cancer therapies The success of Gleevec and related drugs has inspired researchers to step up their hunt for the molecular defects underlying other cancers. |
The Motley Fool
December 14, 2010
Brian Orelli |
An Ounce of Prevention, a Pound of Blockbuster Sales Amgen's Xgeva recently gained Food and Drug Administration approval to treat cancer patients that have bone metastasis. |
The Motley Fool
June 6, 2011
Luke Timmerman |
Exelixis Zeroes In on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients Is Exelixis' risky bet about to pay off? |
The Motley Fool
November 1, 2011
Brian Orelli |
Not Such an Excellent Outcome With the FDA Exelixis gets knocked down for not getting an SPA. |
The Motley Fool
December 14, 2007
Brian Lawler |
Ignore the Dendreon Hoopla A Congressional probe request will have no effect on Dendreon or Provenge's odds at making it through the FDA, since it was not the FDA reviewers of the Provenge marketing application that were accused of anything bad. |
Nursing
October 2010
Linda Schiech |
HPV-related cancer: An equal opportunity danger Although many people know that HPV infections are the leading cause of cervical cancer, they might be surprised to learn that HPV is also associated with other kinds of cancer, including cancers of the head and neck, and anal and penile cancers. |
